Jong-Il Park

Jong-Il Park

Auto-generated profile, based on publicly available information

Jong-Il Park

Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Clinical Cardiology
Verified
Journal Article
Open access
JKJee‐Heon Kim
Jee‐Heon Kim
YYYoung‐Chae Yoon
Young‐Chae Yoon
YKYoung‐Hoon Kim
Young‐Hoon Kim
JPJong‐Il Park
Jong‐Il Park
KCKang-Un Choi
Kang-Un Choi
UKUng Kim
Ung Kim
Background: Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have been demonstrated to decrease cardiovascular adverse events. However, there is little real‐world clinical evidence regarding a direct comparison between dapagliflozin and empagliflozin in patients with diabetes mellitus (DM).Hypothesis: A difference in the cardiovascular efficancy of dapagliflozin versus empagliflozin in DM patients was anticipated, aiming to guide the optimal choice of SGLT2 inhibitors based on cardiovascular outcomes.Methods: From 2014 to 2020, a total of 1549 patients with DM who were prescribed SGLT2 inhibitors such as dapagliflozin or empagliflozin were retrospectively enrolled. We categorized the study population into two groups: dapagliflozin (n = 981) and empagliflozin group (n = 568). The primary endpoint was major adverse cardiovascular events (MACE), defined as a composite of all‐cause death, myocardial infarction (MI), stroke, or hospitalization for heart failure (HF) over a 3‐year period.Results: Propensity‐score matching was performed (537 patients in each group). The mean age and hemoglobin A1c were 58.2 ± 13.0 years and 8.4 ± 1.7%, respectively. There was no significant difference between the dapagliflozin and empagliflozin groups in the risk of MACE (3.7% vs. 4.8%, hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.73–2.35; p = 0.349). Furthermore, there were no differences between the two groups in secondary endpoints including all‐cause death, MI, stroke, and hospitalization for HF. Prior MI and history of HF were independent predictors of MACE.Conclusions: Dapagliflozin and empagliflozin showed no significant difference of real‐world clinical cardiovascular outcomes in patients with DM over a 3‐year period. Further large randomized clinical trials will be warranted for better evaluation.

1 January 2024 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
JPJong-Il Park
Jong-Il Park
YKYoung-Guk Ko
Young-Guk Ko
JLJun-Won Lee
Jun-Won Lee
CAChul-Min Ahn
Chul-Min Ahn
SRSeung-Woon Rha
Seung-Woon Rha
DCDonghoon Choi
Donghoon Choi
Park JI, et al. Korean Circ J. 2024 Apr;54:e49. https://doi.org/10.4070/kcj.2024.0006

5 August 2022 in Medicine
Verified
Journal Article
Open access
JPJong-Il Park
Jong-Il Park
SPSeung-Woo Park
Seung-Woo Park
MKMin-Ji Kwon
Min-Ji Kwon
JLJeon Lee
Jeon Lee
HKHong-Ju Kim
Hong-Ju Kim
DSDong-Gu Shin
Dong-Gu Shin
Catheter ablation (CA) is a well-established therapy for rhythm control in atrial fibrillation (AF). However, CA outcomes for persistent AF remain unsatisfactory because of the high recurrence rate despite time-consuming efforts and the latest ablation technology. Therefore, the selection of good responders to CA is necessary. Surface electrocardiography (sECG)-based complexity parameters were tested for the predictive ability of procedural termination failure during CA and late recurrence of atrial arrhythmias (AA) after CA. A total of 130 patients with nonparoxysmal AF who underwent CA for the first time were investigated. A 10-second sECG of 4 leads (leads I, II, V1, and V6) was analyzed to compute the fibrillatory wave amplitude (FWA), dominant frequency (DF), spectral entropy (SE), organization index (OI), and sample entropy (SampEn). The study endpoints were procedural termination failure during CA and late (≥1 year) AA recurrence after CA. In the multivariate analysis, FWA in lead V1 and DF in lead I were independent predictors of successful AF termination during CA (P <.05). The optimal cut-off values for FWA in lead V1 and DF in lead I were 60.38 μV (area under the curve [AUC], 0.672; P = .001) and 5.7 Hz (AUC, 0.630; P = .016), respectively. The combination of FWA of lead V1 and DF of lead I had a more powerful odds ratio for predicting procedural termination failure (OR, 8.542; 95% CI, 2.938–28.834; P < .001). FWA in lead V1 was the only independent predictor of late recurrence after CA. The cut-off value is 65.73 μV which was 0.634 of the AUC (P = .009). These sECG parameters, FWA in lead V1 and DF in lead I, predicted AF termination by CA in patients with nonparoxysmal AF. In particular, FWA in lead V1 was an independent predictor of late recurrence of AA after CA.

14 December 2023 in The American Journal of Cardiology
Verified
Journal Article
Open access
JPJong-Il Park
Jong-Il Park
JSJi-Hyun Song
Ji-Hyun Song
YBYeong-Hui Bae
Yeong-Hui Bae
YCYu-Hyun Cho
Yu-Hyun Cho
BSByeong-Ju Son
Byeong-Ju Son
UKUng Kim
Ung Kim
There are little direct comparative evidences of strategies between ≥50% and the absolute target goal of low-density lipoprotein cholesterol (LDL-C) level <55 mg/100 ml for the patients who underwent percutaneous coronary intervention (PCI). This study aimed to investigate the clinical impact of different strategies between 2 groups of patients who underwent PCI. A total of 3,104 patients with previous PCI were retrospectively enrolled from 2014 to 2020 at Yeungnam University Medical Center. The study population was stratified into 2 groups based on whether the LDL-C level was <55 mg/100 ml at the 1-year mark or not. Furthermore, the 50% reduction rate of LDL-C was also categorized based on whether it had decreased by ≥50% from the initial LDL-C level at the 1-year mark. The primary end point was 3-year major adverse cardiovascular events (MACEs) which were defined as a composite of cardiovascular death, nonfatal myocardial infarction, target lesion revascularization, hospitalization for heart failure, or nonfatal stroke. There was no significant difference between the LDL <55 mg/100 ml group and the LDL ≥55 mg/100 ml group in the risk of MACEs (hazard ratio 1.06, 95% confidence interval 0.81 to 1.38, p = 0.690) after propensity score matching. However, the group that achieved ≥50% reduction of LDL-C from baseline LDL-C level showed a significant reduction in the occurrence of MACEs in the subgroup of LDL-C level ≥55 mg/100 ml (hazard ratio 0.41, 95% confidence interval 0.19 to 0.89, p = 0.025) compared with the group with <50% reduction of LDL-C. In all patients, the achievement rate of target LDL-C <55 mg/100 ml and more than 50% reduction from baseline was 17.2%. In conclusion, guideline-directed management strategy of ≥50% reduction of LDL-C from the baseline will be needed to reduce the incidence of MACEs in patients with LDL-C ≥55 mg/100 ml who underwent PCI. Additional efforts to increase the target goal achievement rate of LDL-C are warranted.

1 January 2025 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
SKSun Oh Kim
Sun Oh Kim
JPJong-Il Park
Jong-Il Park
UKUng Kim
Ung Kim
Kim SO, et al. Korean Circ J. 2024 Oct;55:e13. https://doi.org/10.4070/kcj.2024.0327

1 January 2026 in Journal of Cardiovascular Intervention
Verified
Journal Article
Open access
PDF file
JPJong-Il Park
Jong-Il Park
UKUng Kim
Ung Kim
Park JI, et al. J Cardiovasc Interv. 2026 Jan;5(1):23-37. https://doi.org/10.54912/jci.2025.0023